mopdf.com

FINANCIAL INTEREST DISCLOSURESBrandonAyresAllergan: Speakers BureauAlcon: Speakers BureauBausch & Lomb: Speakers BureauShire: ConsultantOmeros: ConsultantKala: ConsultantEye Point: ConsultantZeiss: ConsultantLamisBaydounDORC International BV/Dutch Ophthalmic USA: ConsultantPeterBedardBrightStar Therapeutics: Patent HolderWinstonChamberlainOyster Point Pharma: Scientific/Medical Advisory Board MemberLeo Pharma: Scientific/Medical Advisory Board MemberAslan Pharmaceuticals: Scientific/Medical Advisory Board MemberCambium Medical Technologies: Scientific/Medical Advisory Board MemberSunilChauhanClaris Bio: Stock ShareholderAramis Bio: Stock ShareholderJosephCiolinoORA: ConsultantTherOptix: Stock ShareholderKathrynColbyGlaxo Smith Kline: ConsultantWL Gore, Inc: ConsultantKowa: Research Grant Overall Principal InvestigatorKowa: Research Grant Site Principal InvestigatorRezaDanaNovartis: ConsultantAramis Biosciences: Stock ShareholderKera Therapeutics: Stock ShareholderBoston Eye Diagnostics: Stock ShareholderClaris Biotherapeutics: Stock ShareholderDOD-CDMRP: Research Grant Site Principal InvestigatorKala: ConsultantNIH R01 12963: Research Grant Site Principal InvestigatorNIH R21 EY029387: Research Grant Site Principal InvestigatorNIH R01 20889: Research Grant Site Principal InvestigatorGelMEDIX: Stock ShareholderGSK: ConsultantKarenDeMarcoLions Eye Institute for Transplant and Research: EmployeeSophieDengDompe: ConsultantClaris Biotherapeutics: Scientific/Medical Advisory Board MemberNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESAliDjalilianNovartis: ConsultantCombangio: ConsultantMarjanFaridJohnson & Johnson Vision: ConsultantKALA: ConsultantNovartis: ConsultantAllergan: ConsultantBiotissue: ConsultantCorneaGen: ConsultantSightLife: Corporate Board MemberDompe: ConsultantBaush and Lomb: ConsultantZeiss: ConsultantTarsus: ConsultantAsimFarooqGlaxoSmithKline: ConsultantAmgen: ConsultantAmbrx: ConsultantElizabethFoutFlorida Lions Eye Bank: EmployeeSimonFungDompe: Research Grant Overall Principal InvestigatorSanten: ConsultantDaiichi: ConsultantAndreasGlatzOculus, Wetzlar, Germany: OtherFarhadHafeziEMAGine AG: Stock ShareholderPedramHamrahDompe: Research Grant Site Principal InvestigatorCoopervision: Research Grant Site Principal InvestigatorShire: Research Grant Site Principal InvestigatorAllergan: Research Grant Site Principal InvestigatorOKYO: Research Grant Site Principal InvestigatorNational Eye Institute: Research Grant Site Principal InvestigatorSanten: ConsultantOcunova: ConsultantOKYO: ConsultantNovartis: Research Grant Overall Principal InvestigatorNovaliq: Scientific/Medical Advisory Board MemberDompe: Scientific/Medical Advisory Board MemberNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESEdwardHollandHanall, Hovione, IanTECH, Imprimis Pharma: ConsultantInvirsa, Johnson & Johnson Vision Care, Kala Pharmaceuticals: ConsultantKatena, KeraKlear, Licrieye, Mati Pharmaceuticals: ConsultantMerck KGgA,MG Thera, Mintz, Nanowafer, Inc: ConsultantNovaliq, Novartis NIBR, Novartis Pharmaceuticals: ConsultantNovartis Surgical, Ocunexus, Ocuphire, Omeros: ConsultantOphthotech, Oyster Point, Precise Bio, Prometic: ConsultantReGenTree, LLC, Retear, Senju, Shire, Sight Sciences: ConsultantSightLife, Silktech, Slack, Stuart Therapeutics, Takeda Coordination, Tarsus,Tearfilm Innovations, TearLab, TissueTech, Topivert Pharma Limited, Vomaris,WL Gore and Associates, Zeiss: ConsultantJoshuaHouBrightstar Therapeutics: Patent HolderSandeepJainOcugen, Inc: ConsultantNeutrolis, Inc: ConsultantAdvaite, Inc: Corporate Board MemberSelagine, Inc: Stock ShareholderBennieJengOyster Point Pharma: ConsultantUlaJurkunasKowa Grant Support: Research Grant Site Principal InvestigatorSteveKaneBiotissue: ConsultantAdamKaufmanAlcon: Consultant1800Contacts: ConsultantBausch & Lomb: ConsultantW. BarryLeeNovartis: Speakers BureauGore Pharmaceuticals: ConsultantBioTissue: Speakers BureauDompe: ConsultantJohnson & Johnson: ConsultantEyeVance: ConsultantMarianMacsaiTrefoil: ConsultantAllergan: ConsultantInversa: ConsultantGlaukos: Scientific/Medical Advisory Board MemberNovartis: Speakers BureauBruder: Scientific/Medical Advisory Board MemberEyevance: Stock ShareholderOyster Point Pharma: EmployeePriyaMathewsW. L. Gore and Associates: ConsultantSun Pharmaceutical: Speakers BureauNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESEricMeineckeGeorgia Eye Bank:EmployeeShahzadMianKOWA: Research Grant Site Principal InvestigatorVisionCare: Research Grant Site Principal InvestigatorDOD: Research Grant Site Principal InvestigatorNovartis: Research Grant Site Principal InvestigatorAndover Eye Associates: Research Grant Site Principal InvestigatorKamiarMireskandariBayer: Research Grant Site Principal InvestigatorSanten Canada Inc: Scientific/Medical Advisory Board MembeNovartis: Scientific/Medical Advisory Board MemberVictorPerezAlcon: Research Grant Overall Principal InvestigatorEyeGate: Scientific/Medical Advisory Board MemberKala: ConsultantNovartis: Scientific/Medical Advisory Board MemberNovartis: Research Grant Site Principal InvestigatorEyeGate: Stock ShareholderTrefoil: Scientific/Medical Advisory Board MemberTrefoil: Stock ShareholderChristinaPrescottJohnson and Johnson Vision: ConsultantSanten: ConsultantMichelle K.RheeOcular Therapeutix: Research Grant Site Principal InvestigatorNovaBay: Scientific/Medical Advisory Board MemberCynthiaRobertsOculus: ConsultantZiemer: ConsultantAlfonsoSabaterTissueCor, LLC: Stock ShareholderDivyaSrikumaranAlcon: ConsultantMichaelStraikoWL Gore: ConsultantMichaelSzkarlatEversight: EmployeeMichaelTaravellaInnovia Medical: OtherMarkTerryBausch & and Lomb Surgical: Patent HolderMoria: Unrestricted Educational Grant for Annual EKG BreakfastMichaelTitusEversight: EmployeeNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

FINANCIAL INTEREST DISCLOSURESElmerTuEversight: Scientific/Medical Advisory Board MemberGSK: ConsultantOyster Point Pharma: Scientific/Medical Advisory Board MemberDaiichi Sankyo: ConsultantDompe: ConsultantKatrinWackerProQR Therapeutics, the Netherlands: ConsultantJiaYinKera Therapeutics: OwnerChingYuanBrightStar Therapeutics: Patent HolderMadelineYungEBAA Pilot Research Grant: Research Grant Overall Principal InvestigatorNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

PROGRAM SCHEDULENEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

PROGRAM SCHEDULERegistration: 7:00 am – 2:00 pmBreakfast:7:00 am – 8:00 amSECTION I8:00 am – 8:03 amWelcome and IntroductionsSophie Deng, MD, PhD, and Marjan Farid, MD8:04 am – 8:50 amINVITED SESSION: FUTURE OF THE TREATMENT OF CORNEAL ENDOTHELIALAND STROMAL DISEASEPresenters:Jorge Alió, MD, PhD, FEBO, University Miguel Hernández of ElcheKathryn Colby, MD, PhD, NYU Langone HealthUla Jurkunas, MD, Mass Eye and EarJodhbir Mehta, MBBS, FRCOphth, FRCS(Ed), FAMS, PhD, Singapore National EyeCentre8:51 am – 9:02 amTopical Ivmed-80 Eyedrops for Pharmacologic Crosslinking of Keratoconuswithout UV Light or SurgeryBalamurali Ambati, MD, PhD, Pacific Clear Vision Institute9:03 am – 9:14 amNicergoline: A Potential Novel Treatment for Severe Persistent Corneal EpithelialDefectsValeria Oliva-Biénzobas, MD, Centro de la Vision9:15 am – 9:26 amTopical 1% 5-fluorouracil as Primary Treatment for Ocular Surface SquamousNeoplasia: Long-Term Follow-up StudyAdam Wylegala, MD, DMS, FEBO,** Bascom Palmer Eye Institute9:27 am – 9:38 amPhlyctenular Disease Associated with Increased Incidence and Severe CornealSequelae in Hispanic Pediatric PatientsAaron R. Kaufman, MD,* University of Illinois at Chicago, Illinois Eye and Ear Infirmary9:39 am – 9:50 amOutcomes of Fluid-Filled Scleral Lens Devices for the Management of LimbalStem Cell DeficiencyClémence Bonnet, MD, Stein Eye Institute, UCLA9:51 am – 10:05 amCornea Society Business Meeting10:05 am – 10:20 amBreak* ResidentNEW ORLEANS,LAFRIDAY, NOVEMBER12** CorneaFORUM 2021Fellow

PROGRAM SCHEDULESECTION II10:20 am – 10:21 amWelcome BackMarjan Farid, MD, and Sophie Deng, MD, PhD10:22 am – 10:24 am2021 EBAA High Impact Research Grant Award AnnouncementBennie Jeng, MD, Chair, EBAA Research Committee10:25 am – 10:36 amEffect of Increasing Povidone Iodine (PVP-I) Exposure on Tissue Quality andImpact on Donor Rim CulturesOnkar Sawant, PhD, Eversight10:37 am – 10:48 amDouble Povidone Iodine Wash: Effectivity in Reducing the Infection Rate ofRecovered Corneal TissueStephen C. Kaufman, MD, PhD, University of Minnesota10:49 am – 11:00 amInduction of Antimicrobial Peptide Expression in Human Donor Corneas UsingAndrographolideMadeline Yung, MD, University of California, Davis11:01 am – 11:12 amThe Impact of Amphotericin B Fortified Preservation Media on Rates ofEndothelial Keratoplasty DetachmentVincent Hussey, MS, University of California, Irvine11:13 am – 11:24 amEndophthalmitis Rates Following Cornea Surgery in the Medicare Populationfrom 2016 to 2019Fasika Woreta, MD, MPH, Wilmer Eye Institute11:25 am – 11:36 amThe Microbiome in Stevens-Johnson SyndromeMichael Zilliox, PhD, Loyola University Chicago11:37 am – 11:41 amR. Townley Paton IntroductionStephen C. Kaufman, MD, PhD, 2020 R. Townley Paton Award RecipientMark Mannis, MD, 1996 R. Townley Paton Award Recipient11:42 am – 12:05 pmR. Townley Paton Lecture: Well-Behaved Women Seldom Make History:The Advancement of Women in OphthalmologyJennifer Li, MD, 2021 R. Townley Paton Award Recipient12:06 pm – 12:10 pmClosing MedicalNEW ORLEANS,LA StudentFRIDAY, NOVEMBER 12FORUM 2021

PROGRAM SCHEDULER. TOWNLEY PATON LUNCHEON12:15 pm – 1:25 pmR. Townley Paton LuncheonIncludes a seated lunch and a moderated discussion. Physician attendees are invited.SECTION III1:30 pm – 1:31 pmAfternoon Session WelcomeSophie Deng, MD, PhD, and Marjan Farid, MD1:32 pm – 1:43 pmDescemet Membrane Endothelial Keratoplasty (DMEK): 10-year ClinicalOutcomes and Graft SurvivalViridiana Kocaba, MD, PhD, FEBO, Netherlands Institute for Innovative OcularSurgery (NIIOS)1:44 pm – 1:55 pmTwo Year Changes in Corneal Power after Endothelial Keratoplasty: Results fromthe Randomized Controlled DETECT TrialWinston Chamberlain, MD, PhD, Oregon Health & Science University1:56 pm – 2:07 pmPrimary Graft Failure Following Descemet Membrane Endothelial KeratoplastyUsing Nondiabetic Donor TissueAndrea Blitzer, MD,** University of Iowa2:08 pm – 2:19 pmDoes the Size and Duration of the Bubble in DMEK Surgery Affect theAttachment and Endothelial Cell Loss of the DMEK Graft?Jessica Chen, MD,** Devers Eye Institute2:20 pm – 2:31 pmComparison of Graft Viability in Tri-Folded Endothelium-In and ScrolledEndothelium-Out Preloaded Descemet Membrane Endothelial KeratoplastyMatthew Hartman, MD, Southeast Eye Specialists2:32 pm – 2:43 pmDifference in Postoperative Graft Adherence Between Descemet MembraneEndothelial Keratoplasty with and without Cataract SurgeryAnne-Marie Kladny, MD,* University of Freiburg2:44 pm – 2:55 pmNovel Preloaded Injectable UT-Descemet’s Stripping Automated EndothelialKeratoplasty (UT-DSAEK): No Touch Surgical Technique and Early Surgical ResultsSteven Kane, MD, Tailored Eyes2:56 pm – 3:07 pmAn Alternative Time Efficient Method to Specular Microscopy Following DMEKPreparation Using Trypan Blue StainingMichael Szkarlat, BS, Eversight* ResidentNEW ORLEANS,LAFRIDAY, NOVEMBER12** CorneaFORUM 2021Fellow

PROGRAM SCHEDULE3:08 pm – 3:10 pmRichard Troutman Prize Award IntroductionKathryn Colby, MD, PhD, NYU Langone Health3:11 pm – 3:20 pmRichard Troutman Prize Lecture: Accelerated Epi-On Versus StandardEpi-Off Corneal Collagen Cross-Linking for Progressive Keratoconus in PediatricPatients: Five Years of Follow-UpMaria A. Henriquez, MD, MSc, PhD, Oftalmosalud Instituto de Ojos3:20 pm – 3:35 pmBreakSECTION IV3:35 pm – 3:36 pmWelcome BackMarjan Farid, MD, and Sophie Deng, MD, PhD3:37 pm – 4:07 pmINVITED SESSION: Future of Artificial CorneaPresenters:Esen Akpek, MD, Johns Hopkins UniversityJulie Daniels, PhD, University College LondonAnthony Aldave, MD, Stein Eye Institute, UCLA4:08 pm – 4:19 pmRegulatory T-cells Promote Corneal Graft Survival by Modulating PostTransplantation Alloimmune ResponseHamid Alemi, MD, MPH, Schepens Eye Research Institute/ Massachusetts Eye andEar4:20 pm – 4:31 pmAssociation Between Anti-Human Leukocyte Antigen (HLA) Antibodies and GraftRejection in Pediatric KeratoplastyAngela Zhu, MD, Bascom Palmer Eye Institute, University of Miami4:32 pm – 4:43 pmHyaluronic-Acid Based Bioengineered Corneal Stromal SubstituteRoza Vaez Ghaemi, PhD, University of British Columbia4:44 pm – 4:55 pmProspective, Randomized, Multicenter, Double-Masked, Clinical Trial EvaluatingCorneal Crosslinking of Keratoprosthesis Carrier TissueJoseph B. Ciolino, MD, Schepens Eye Institute/ Mass Eye and Ear4:56 pm – 4:59 pmBest Paper of Session Award PresentationSupported by an unrestricted educational grant from Lions Gift of Sight5:00 pmClosing RemarksSophie Deng, MD, PhD, and Marjan Farid, MDNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

SAVE THE DATE!

INVITED SESSIONSNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

INVITED SESSIONSFuture of the Treatment of Corneal Endothelialand Stromal DiseaseSECTION I: 8:04 AM – 8:50 AMUtilizing Mesenchymal Stem Cells for the Treatment of KeratoconusJorge Alió, MD, PhD, FEBO, University Miguel Hernández of ElcheCurrent Status of Descemet Stripping Only (DSO)Kathryn Colby, MD, PhD, NYU Langone HealthAntioxidant Treatments for Fuchs Dystrophy: What is New?Ula Jurkunas, MD, Mass Eye and EarCultivated Endothelial Cell Sheets for Endothelial FailureJodhbir Mehta, MBBS, FRCOphth, FRCS(Ed), FAMS, PhD, Singapore National Eye CentreModerated Q&AAll presentersFuture of Artificial CorneaSECTION IV: 3:37 PM- 4:07 PMThe Predicted Future of the Artificial Cornea and Where are We Headed?Anthony Aldave, MD, Stein Eye Institute, UCLABiocompatibility of a Novel Synthetic Corneal DeviceEsen Akpek, MD, Johns Hopkins UniversityCornea Equivalent for the Treatment of Stromal DiseaseJulie Daniels, PhD, University College LondonModerated Q&AAll presentersNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

AWARD LECTURESNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

AWARD LECTURESR. TOWNLEY PATON AWARD LECTUREWell-Behaved Women Seldom Make History:The Advancement of Women in OphthalmologyJennifer Li, MD, University of California, Davis/Sierra Donor Services Eye Bank2021 R. Townley Paton Award RecipientApproximately 150 years ago, Isabel Hayes Chapin Barrows became the first woman to practiceophthalmology in the United States. Since that time, women have made tremendous strides withinophthalmology. During this year’s Paton Lecture, we will celebrate the pioneering women who havehelped pave the way for us, and reflect on how far we have come in our efforts to break down the gendergap. We will also explore areas where further progress is still needed for women in ophthalmology.RICHARD TROUTMAN PRIZE LECTUREAccelerated Epi-On Versus Standard Epi-Off CornealCollagen Cross-Linking for Progressive Keratoconus inPediatric Patients: Five Years of Follow-Up*Maria A. Henriquez, MD, MSc, PhD, Oftalmosalud Instituto de OjosCo-Authors: Gustavo Hernandez-Sahagun, MD, Jorge Camargo, MD, and Luis Izquierdo, Jr, MD, MSc, PhDPurpose: The purpose of this study was to evaluate and compare the 5-year efficacy and safety ofaccelerated transepithelial (A-epi-on) corneal collagen cross-linking (CXL) with standard CXL (epi-off) inchildren with progressive keratoconus (KC).Methods: This prospective cohort study included 78 eyes of patients aged 18 years old or younger withprogressive KC who underwent CXL at the Oftalmosalud Institute of Eyes, Lima, Peru. A-epi-on CXL wasperformed in 32 eyes (309 of impregnation/59 of irradiation at 18 mW/cm2) and epi-off CXL was performedin 46 eyes (309of impregnation/309 minutes of irradiation at 3 mW/cm2). Visual acuity, refraction, and theScheimpflug imaging parameters were evaluated preoperatively and postoperatively at 1 and 5 years.Results: The best corrected visual acuity improved to 0.06 logarithm of the minimum angle of resolution(SD: 0.19, P 0.03) and 0.09 logarithm of the minimum angle of resolution (SD: 0.13, P, 0.001) in the A-epion and epi-off groups, respectively. The mean flattening in the mean keratometry was 0.09 diopters (D)(SD: 0.68, P 0.33) and 3.18 D (SD: 5.17, P, 0.001) in the A-epi-on CXL and Epi-off groups at the 5-yearfollow-up. Significant differences were found in the change at 1 and 5 years between the groups forcylinder reduction, flat and mean K, and pachymetry (all P, 0.05). The KC progression rate was 9.37%(3/32) in the A-epi-on CXL; no progression was found in the epi-off CXL group at the 5-year follow-up.Conclusions: Both procedures halted the progression of KC at the 5-year follow-up; however, epi-offCXL was safer and more effective when compared with A-epi-on CXL.*Originally published in Cornea Volume 39, Number 12, December 2020NEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

SCIENTIFIC ABSTRACTSNEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

SCIENTIFIC ABSTRACT8:51 am – 9:02 amTopical Ivmed-80 Eyedrops for Pharmacologic Crosslinking of Keratoconus without UV Lightor SurgeryBalamurali Ambati, MD, PhD, Pacific Clear Vision InstituteCo-Authors: Sarah Molokhia, PhD; Hironori Uehara, PhD; Arturo Chayet, MD; Cynthia Roberts, PhD; Sabine Kling, PhD;and Farhad Hafezi, PhDPurpose: To determine whether IVMED-80 eyedrops, which increase lysyl oxidase, can flatten the cornea in patientswith keratoconus.Methods: Pre-clinical IVMED-80 studies determined if it increased LOX activity of keratoconic fibroblasts and rabbitcorneas, improved human donor and rabbit corneal biomechanics, and flattened rabbit corneas. A Phase 1/2aprospective, randomized, double-masked, controlled trial was performed to determine the safety and preliminaryefficacy of BID dosing of IVMED-80 eyedrops ind 36 patients with a history of progressive keratoconus, between18 to 42 years of age. Three subarms included vehicle control, 6 and 16 weeks of therapy, with 6 months follow-up.Endpoints included Kmax, BCVA, endothelial cell count, IOP, and adverse event analysis.Results: IVMED-80 increased LOX activity of fibroblasts 4-fold, and flattened rabbit corneas by 1.8 diopters with 6weeks of treatment. Four month clinical trial follow-up data is currently available. In patients (mean age of 27.3 /- 6.8years), we observed flattening of Kmax by 1.0 diopters in the 16 week therapy group, while the 6 week therapy grouphad initial flattening of 0.40 diopters at 1 month, but rebounded to baseline by month 4. Vehicle-treated patientsdemonstrated continued progression. No significant changes on BCVA, endothelial cell count, or IOP were observed.No adverse events were observed.Conclusion: IVMED-80 induces pharmacologic crosslinking by delivering copper to increase corneal LOX, whichgenetic and biochemical studies show is reduced in keratoconus. We demonstrate improved donor and rabbit cornealbiomechanics, and flattening of rabbit corneas. IVMED-80 reduced Kmax of 1.0 D with 16 weeks of therapy in patientswithout adverse events.NEW ORLEANS, LAFRIDAY, NOVEMBER 12FORUM 2021

SCIENTIFIC ABSTRACT9:03 am – 9:14 amNicergoline: A Potential Novel Treatment for Severe Persistent Corneal Epithelial DefectsValeria Oliva-Biénzobas, MD, Centro de la VisionCo-Authors: Alejandro Navas; Victor Boullosa; A

Albert Einstein College New York, NY Marian S. Macsai, MD Oyster Point Pharma Chicago, IL Saira Quraishy, CEBT Georgia Eye Bank Atlanta, GA Divya Srikumaran, MD Wilmer Eye Institute Baltimore, MD Pedram Hamrah, MD Tufts Medical Center Boston, MA . Chamberlain, MD, PhD Medical Advisory Board